FENC

Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients

Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™

Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action - FENC

FENC Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Lead Plaintiff Deadline: November 2, 2020